Program
follitropin alfa
Also written as “Gonal-f”, “Follitropin alfa (Primapur)” and “Gonal-f®”.
Its studies are mostly in Infertility · Infertility, Female · Hypogonadism · Anovulation, led by 10 companies.
Drug pageFollitropin alfa: every studyMany companies study it; this page follows only the 23 they lead. All 49 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germanyits history only | 131 open or running | phase 4since Nov 4, 2005 | Nov 4, 2005 | Sep 30, 2027phase 3 · NCT07340827 |
| IVFarma | 20 open or running | phase 3since Mar 2, 2017 | Mar 2, 2017 | none ahead |
| Bharat Serums and Vaccinesits history only | 11 open or running | phase 3since Jan 23, 2022 | Jan 23, 2022 | none ahead |
| Changchun GeneScience Pharmaceuticalits history only | 10 open or running | phase 3since Jan 5, 2015 | Jan 5, 2015 | none ahead |
| Fertility Biotechits history only | 10 open or running | phase 1since May 19, 2015 | May 19, 2015 | none ahead |
| Finoxits history only | 10 open or running | phase 3since May 10, 2010 | May 10, 2010 | none ahead |
| Gema Biotechits history only | 10 open or running | phase 3since May 22, 2015 | May 22, 2015 | none ahead |
| IBSA Institut Biochimiqueits history only | 10 open or running | phase 3since Sep 15, 2006 | Sep 15, 2006 | none ahead |
| MinaPharm Pharmaceuticalsits history only | 10 open or running | phase 4since Nov 30, 2016 | Nov 30, 2016 | none ahead |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 1since Mar 4, 2025 | Mar 4, 2025 | none ahead |
Also a collaborator on its studies: Merck Serono Middle East FZ, Merck Serono GmbH, Germany, Merck Serono Co., Ltd., Japan and Merck Serono S.P.A., Italy.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of IVFarma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 2, 2017First study: phase 3 study in Infertility, FemaleFirst studyNCT03088137 · 118 enrolled · Russian Federation
- Feb 26, 2019Phase 1 study in Area Under CurveNCT03857230 · 28 enrolled · Russian Federation
TargetBeta
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule
Other programs on FSHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Follicle Stimulating Hormonerule | glycotope-gmbh | phase 4 | 6 |
| follitropin deltarule | Ferring Pharmaceuticals | phase 3 | 18 |
Studies
All 2 IVFarma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03857230Area Under Curve · Russian Federation | 1 | Completed | May 10, 2016 | 28 |
| NCT03088137Infertility, Female · Russian Federation | 3 | Completed | Aug 17, 2018 | 118 |
How it is read
Names in the registry
- “Gonal-f”, 2 entries
- “Follitropin alfa (Primapur)”, 2 entries
- “Gonal-f®”, 2 entries
- “GONAL-f®”, 2 entries
- “GONAL f® prefilled pen”, 2 entries
Conditions, from the studies’ own filings
- Infertility, 15 studies
- Infertility, Female, 5 studies
- Hypogonadism, 1 study
- Anovulation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.